Search Results - "QUAGLINO, P."

Expression of cytokines, chemokines and other effector molecules in two prototypic autoinflammatory skin diseases, pyoderma gangrenosum and Sweet's syndrome by Marzano, A. V., Fanoni, D., Antiga, E., Quaglino, P., Caproni, M., Crosti, C., Meroni, P. L., Cugno, M.

“…Summary Pyoderma gangrenosum (PG) and Sweet's syndrome (SS) are two inflammatory skin diseases presenting with painful ulcers and erythematous plaques,…”
Get full text

Collaborative efforts in studying Mediterranean melanoma families: A step towards precision medicine by Ribero, S., Quaglino, P., Roccuzzo, G.

Get full text

Impact of comorbidities in elderly and frail patients and response to biological therapy in psoriasis by Rosset, F., Mastorino, L., Dapavo, P., Quaglino, P., Ribero, S.

Get full text

‘Efficacy of anti‐IL‐23 and anti‐IL‐17 after adalimumab failure in psoriatic patients’—response to Yu et al by Mastorino, L., Ortoncelli, M., Dapavo, P., Ribero, S., Quaglino, P.

Get full text

Efficacy of tralokinumab after failure with upadacitinib and dupilumab in a patient affected by atopic dermatitis by Mastorino, L., Gelato, F., Quaglino, P., Ortoncelli, M., Ribero, S.

Get full text

Prognostic factors, prognostic indices and staging in mycosis fungoides and Sézary syndrome: where are we now? by Scarisbrick, J.J., Kim, Y.H., Whittaker, S.J., Wood, G.S., Vermeer, M.H., Prince, H.M., Quaglino, P.

“…Summary Mycosis fungoides is the most prevalent form of primary cutaneous T‐cell lymphoma. Patients frequently present with early‐stage disease typically…”
Get full text

Sentinel Lymph Node Biopsy in Thick-Melanoma Patients (N=350): What is Its Prognostic Role? by Ribero, S., Osella-Abate, S., Sanlorenzo, M., Balagna, E., Senetta, R., Fierro, M.T., Macripò, G., Macrì, L., Sapino, A., Quaglino, P.

“…Background Sentinel lymph node biopsy (SLNB) is currently recommended for patients with intermediate-thickness melanomas (T2–T3). Historically, T4 melanoma…”
Get full text

Efficacy of anti‐IL‐23 and anti‐IL‐17 after adalimumab failure in psoriatic patients by Mastorino, L., Susca, S., Cariti, C., Sliquini, N., Verrone, A., Stroppiana, E., Ortoncelli, M., Dapavo, P., Ribero, S., Quaglino, P.

“…Background Many national guidelines at the European level recommend first‐line therapy based on the anti‐TNF‐alpha adalimumab for treatment of psoriasis and…”
Get full text

The Treg/Th17 cell ratio is reduced in the skin lesions of patients with pyoderma gangrenosum by Caproni, M., Antiga, E., Volpi, W., Verdelli, A., Venegoni, L., Quaglino, P., Fabbri, P., Marzano, A.V.

Get full text

Rapid remission of atypical cutaneous lobular breast cancer metastases after aromatase inhibitor therapy: a case report and literature review by Parietti, M., Carugno, A., Gianatti, A., Sena, P., Quaglino, P., Vezzoli, P.

Get full text

Electrochemotherapy in the treatment of metastatic malignant melanoma: a prospective cohort study by InspECT by Kunte, C., Letulé, V., Gehl, J., Dahlstroem, K., Curatolo, P., Rotunno, R., Muir, T., Occhini, A., Bertino, G., Powell, B., Saxinger, W., Lechner, G., Liew, S.‐H., Pritchard‐Jones, R., Rutkowski, P., Zdzienicki, M., Mowatt, D., Sykes, A.J., Orlando, A., Mitsala, G., Rossi, C.R., Campana, L., Brizio, M., de Terlizzi, F., Quaglino, P., Odili, J.

“…Summary Background (ECT) is an effective local treatment for cutaneous metastasis. Treatment involves the administration of chemotherapeutic drugs followed by…”
Get full text

Comparison of Secukinumab and Ixekizumab in psoriasis: a real‐life cohort study on the efficacy and drug survival of 445 patients by Cariti, C., Dapavo, P., Mastorino, L., Ortoncelli, M., Siliquini, N., Merli, M., Avallone, G., Giordano, S., Fabrizio, R., Susca, S., Verrone, A., Stroppiana, E., Quaglino, P., Ribero, S.

Get full text

Clinicopathological definition, management and prognostic value of mogamulizumab-associated rash and other cutaneous events: A systematic review by Avallone, G, Roccuzzo, G, Pileri, A, Agostinelli, C, Maronese, C A, Aquino, C, Tavoletti, G, Onida, F, Fava, P, Ribero, S, Marzano, A V, Berti, E, Quaglino, P, Alberti-Violetti, S

“…Mogamulizumab is a first-in-class IgG1k monoclonal antibody that selectively targets the chemokine receptor type 4. The drug has received Food and Drug…”
Get full text

Real‐life comparison between secukinumab and ixekizumab in the treatment of pustular and erythrodermic psoriasis by Avallone, G., Cariti, C., Dapavo, P., Ortoncelli, M., Conforto, L., Mastorino, L., Roccuzzo, G., Cavallo, F., Rubatto, M., Quaglino, P., Ribero, S.

Get full text

Topical ruxolitinib: A new treatment for vitiligo by Tavoletti, G, Avallone, G, Conforti, C, Roccuzzo, G, Maronese, C A, Mattioli, M A, Quaglino, P, Zalaudek, I, Marzano, A V, Ribero, S, Alberti-Violetti, S

“…Vitiligo is a chronic autoimmune skin disorder whose diagnosis is often psychologically upsetting. The efficacy of the available therapies, including topical…”
Get full text

Global patterns of care in advanced stage mycosis fungoides/Sezary syndrome: a multicenter retrospective follow-up study from the Cutaneous Lymphoma International Consortium by Quaglino, P., Maule, M., Prince, H.M., Porcu, P., Horwitz, S., Duvic, M., Talpur, R., Vermeer, M., Bagot, M., Guitart, J., Papadavid, E., Sanches, J.A., Hodak, E., Sugaya, M., Berti, E., Ortiz-Romero, P., Pimpinelli, N., Servitje, O., Pileri, A., Zinzani, P.L., Estrach, T., Knobler, R., Stadler, R., Fierro, M.T., Alberti Violetti, S., Amitay-Laish, I., Antoniou, C., Astrua, C., Chaganti, S., Child, F., Combalia, A., Fabbro, S., Fava, P., Grandi, V., Jonak, C., Martinez-Escala, E., Kheterpal, M., Kim, E.J., McCormack, C., Miyagaki, T., Miyashiro, D., Morris, S., Muniesa, C., Nikolaou, V., Ognibene, G., Onida, F., Osella-Abate, S., Porkert, S., Postigo-Llorente, C., Ram-Wolff, C., Ribero, S., Rogers, K., Sanlorenzo, M., Stranzenbach, R., Spaccarelli, N., Stevens, A., Zugna, D., Rook, A.H., Geskin, L.J., Willemze, R., Whittaker, S., Hoppe, R., Scarisbrick, J., Kim, Y.

“…Advanced-stage mycosis fungoides (MF)/Sézary syndrome (SS) patients are weighted by an unfavorable prognosis and share an unmet clinical need of effective…”
Get full text

Impact of comorbidities in the response of atopic patients treated with dupilumab: a real‐life study up to 36 weeks by Mastorino, L., Cantafio Duò, V.L., Vecco, C., Gelato, F., Giordano, S., Roccuzzo, G., Cavaliere, G., Avallone, G., Ortoncelli, M., Ribero, S., Quaglino, P.

Get full text

Drug survival, effectiveness and safety of ixekizumab for moderate‐to‐severe psoriasis up to 5 years by Mastorino, L., Dapavo, P., Burzi, L., Rosset, F., Giunipero di Corteranzo, I., Leo, F., Verrone, A., Stroppiana, E., Ortoncelli, M., Ribero, S., Quaglino, P.

“…Introduction Ixekizumab proved to be effective and safe for psoriasis treatment in several randomized clinical trials and real‐life studies. Nevertheless,…”
Get full text

Reply to ‘The first dose of COVID‐19 vaccine may trigger pemphigus and bullous pemphigoid flares: is the second dose therefore contraindicated?’ by Damiani G et al by Avallone, G., Giordano, S., Astrua, C., Merli, M., Senetta, R., Conforti, C., Ribero, S., Marzano, A.V., Quaglino, P.

Get full text

Primary cutaneous lymphoma patients seen at a referral dermatological centre in 1 year: A single‐centre observational retrospective cohort study of the diagnoses and staging, comorbidities and associated symptoms, treatment performed and clinical course by Macagno, N., Mastorino, L., Rubatto, M., Avallone, G., Merli, M., Agostini, A., Fava, P., Ribero, S., Quaglino, P.

“…Importance Primary cutaneous lymphomas (PCL) are rare diseases, but the indolent course makes their prevalence high. Although there are many treatment options,…”
Get full text